#pharmaceuticals

GAO Finds Universal Naloxone Coverage But Gaps in High-Potency Countermeasures

A GAO report reveals comprehensive access to standard naloxone across Medicare Part D and Medicaid, but highlights significant cost barriers and coverage gaps for newer over-the-counter formulations and high-potency countermeasures like nalmefene.